Founder and Executive Chairman Mr. Bill Mobbs has released a parcel of his 42% of ITL (4.6m shares) to a Specialist Small Cap Fund Manager and to fellow ITL non-executive Director Mr. Mark Peatey. Mr. Mobbs retains 36% of ITL.
ITL BioMedical, a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce the global launch of its highly innovative patented DonorCare® Needle Guard 2 will take place at the AABB Annual Meeting in Orlando, the premiere event for healthcare professionals in transfusion medicine and cellular therapies. Read More “ITL BioMedical Announces Global Launch of DonorCare Needle Guard 2”
ITL BioMedical, a division of ITL (ASX: ITD) that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce it has signed a global, multi-year distribution agreement for its SampLok® Sampling Kit (SSK) with bioMérieux (Euronext: BIM), a multinational biotechnology company and supplier of bacterial screening test systems and ancillaries. Read More “ITL BioMedical Announces Global Distribution Agreement for SSK with bioMérieux”
ITL Limited, a diversified healthcare company and owner of ITL Healthcare which produces quality invasive blood pressure monitoring systems, is pleased to announce a new five year contract with Macquarie University Hospital (MUH), Australia’s first private not-for-profit teaching hospital, located at Macquarie University in Sydney. Read More “5 Year Contract Win with Macquarie University Hospital”